{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:17:41Z","timestamp":1791944261223,"version":"4.3.4"},"reference-count":140,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.mayocp.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T16:44:52Z","timestamp":1541609092000},"page":"1810-1824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Advances in the Treatment of Sickle Cell Disease"],"prefix":"10.1016","volume":"93","author":[{"given":"Sargam","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia H.","family":"Pecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2865","key":"10.1016\/j.mayocp.2018.08.001_bib1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.110.2865.543","article-title":"Sickle cell anemia, a molecular disease","volume":"110","author":"Pauling","year":"1949","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/1535370216636726","article-title":"Minireview: genetic basis of heterogeneity and severity in sickle cell disease","volume":"241","author":"Habara","year":"2016","journal-title":"Exp Biol Med (Maywood)"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib3","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood.V97.7.2165","article-title":"Stroke in hemoglobin (SD) sickle cell disease with moyamoya: successful hydroxyurea treatment after cerebrovascular bypass surgery","volume":"97","author":"Schmugge","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.001_bib4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood.V68.5.985.985","article-title":"Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene","volume":"68","author":"Steinberg","year":"1986","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2009.07650.x","article-title":"Discovering the genetics underlying foetal haemoglobin production in adults","volume":"145","author":"Thein","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2018.08.001_bib7","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood.V92.10.3924","article-title":"Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes","volume":"92","author":"Sultana","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10739680802279394","article-title":"Sickle red cell-endothelium interactions","volume":"16","author":"Kaul","year":"2009","journal-title":"Microcirculation"},{"issue":"10","key":"10.1016\/j.mayocp.2018.08.001_bib9","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1182\/blood.V87.10.4440.bloodjournal87104440","article-title":"Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst","volume":"87","author":"Hofstra","year":"1996","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2018.08.001_bib10","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1073\/pnas.86.9.3356","article-title":"Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications","volume":"86","author":"Kaul","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00062752-200203000-00003","article-title":"Sickle cell vaso-occlusion: multistep and multicellular paradigm","volume":"9","author":"Frenette","year":"2002","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib12","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-11-056101","article-title":"Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in\u00a0vivo","volume":"110","author":"Zennadi","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2018.08.001_bib13","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2001-12-0289","article-title":"Novel epinephrine and cyclic AMP-mediated activation of BCAM\/Lu-dependent sickle (SS) RBC adhesion","volume":"101","author":"Hines","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.001_bib14","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.052522799","article-title":"Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm","volume":"99","author":"Turhan","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib15","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2006-12-061697","article-title":"Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin","volume":"110","author":"Villagra","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib16","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2141.2000.02353.x","article-title":"Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia","volume":"111","author":"Inwald","year":"2000","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.001_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0022-2143(97)90005-6","article-title":"Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia","volume":"129","author":"Wun","year":"1997","journal-title":"J\u00a0Lab Clin Med"},{"issue":"8","key":"10.1016\/j.mayocp.2018.08.001_bib18","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.V81.8.2137.2137","article-title":"Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion","volume":"81","author":"Brittain","year":"1993","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.blre.2006.06.001","article-title":"Platelet-neutrophil-interactions: linking hemostasis and inflammation","volume":"21","author":"Zarbock","year":"2007","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.mayocp.2018.08.001_bib20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood-2012-11-451229","article-title":"Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins","volume":"121","author":"Schaer","year":"2013","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2018.08.001_bib21","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1182\/blood-2014-07-589283","article-title":"Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease","volume":"125","author":"Camus","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib22","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.V98.6.1802","article-title":"Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase","volume":"98","author":"Wagener","year":"2001","journal-title":"Blood"},{"issue":"4, suppl","key":"10.1016\/j.mayocp.2018.08.001_bib23","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"issue":"17","key":"10.1016\/j.mayocp.2018.08.001_bib24","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.mayocp.2018.08.001_bib25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM198606193142501","article-title":"Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial","volume":"314","author":"Gaston","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.mayocp.2018.08.001_bib27","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1056\/NEJMoa050460","article-title":"Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease","volume":"353","author":"Adams","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.mayocp.2018.08.001_bib28","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2012-03-419879","article-title":"BABY HUG Investigators. Impact of hydroxyurea on clinical events in the BABY HUG trial","volume":"120","author":"Thornburg","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib29","doi-asserted-by":"crossref","first-page":"e1001484","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"issue":"24","key":"10.1016\/j.mayocp.2018.08.001_bib30","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","article-title":"Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies","volume":"122","author":"Manwani","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib31","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood-2003-07-2475","article-title":"Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease","volume":"103","author":"Zimmerman","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2018.08.001_bib32","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V79.10.2555.2555","article-title":"Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia","volume":"79","author":"Charache","year":"1992","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.001_bib33","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood.V89.3.1078","article-title":"Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea","volume":"89","author":"Steinberg","year":"1997","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.mayocp.2018.08.001_bib34","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMct0708272","article-title":"Hydroxyurea for the treatment of sickle cell anemia","volume":"358","author":"Platt","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000040964","article-title":"Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy","volume":"102","author":"Saleh","year":"1999","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/10245332.2000.11746528","article-title":"Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea; hemoglobinopathy","volume":"5","author":"Nahavandi","year":"2000","journal-title":"Hematology"},{"issue":"20","key":"10.1016\/j.mayocp.2018.08.001_bib37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.mayocp.2018.08.001_bib38","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib39","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.V88.6.1960.bloodjournal8861960","article-title":"Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial","volume":"88","author":"Ferster","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib40","first-page":"125","article-title":"Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes","volume":"91","author":"de Montalembert","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib41","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-12-4973","article-title":"Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study","volume":"106","author":"Hankins","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2018.08.001_bib42","doi-asserted-by":"crossref","first-page":"939","DOI":"10.7326\/0003-4819-148-12-200806170-00221","article-title":"Systematic review: hydroxyurea for the treatment of adults with sickle cell disease","volume":"148","author":"Lanzkron","year":"2008","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.hoc.2009.11.002","article-title":"Hydroxyurea for children with sickle cell disease","volume":"24","author":"Heeney","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"issue":"24","key":"10.1016\/j.mayocp.2018.08.001_bib44","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2017-06-788935","article-title":"Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia","volume":"130","author":"Opoka","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2018.08.001_bib45","first-page":"CD002202","article-title":"Hydroxyurea (hydroxycarbamide) for sickle cell disease","volume":"4","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2018.08.001_bib46","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V130.Suppl_1.758.758","article-title":"Off-label prescription of hydroxycarbamide (hydroxyurea, HU) for severe anemia: preliminary results from European Non-Interventional, Multicentric, Prospective Escort-HU Study [abstract]","volume":"130","author":"De Montalembert","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2018.08.001_bib47","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/ajh.24906","article-title":"A\u00a0clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy","volume":"92","author":"Estepp","year":"2017","journal-title":"Am J Hematol"},{"issue":"1, suppl 1","key":"10.1016\/j.mayocp.2018.08.001_bib48","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.amepre.2016.01.001","article-title":"Hydroxyurea use in young children with sickle cell anemia in New York State","volume":"51","author":"Anders","year":"2016","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/andr.12370","article-title":"Reproductive endocrine issues in men with sickle cell anemia","volume":"5","author":"Huang","year":"2017","journal-title":"Andrology"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/17474086.2014.959922","article-title":"Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review","volume":"7","author":"DeBaun","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/bdrb.20123","article-title":"NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea","volume":"80","author":"Liebelt","year":"2007","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib52","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ajh.20353","article-title":"Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists\/oncologists","volume":"79","author":"Zumberg","year":"2005","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.mayocp.2018.08.001_bib54","first-page":"968","article-title":"Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network","volume":"100","author":"Lanzkron","year":"2008","journal-title":"J\u00a0Natl Med Assoc"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib55","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24255","article-title":"Effects of hydroxyurea treatment for patients with hemoglobin SC disease","volume":"91","author":"Luchtman-Jones","year":"2016","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.mayocp.2018.08.001_bib56","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib57","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib58","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pbc.24100","article-title":"Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia","volume":"59","author":"Alvarez","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"10.1016\/j.mayocp.2018.08.001_bib59","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","article-title":"Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)","volume":"119","author":"Ware","year":"2012","journal-title":"Blood"},{"issue":"9778","key":"10.1016\/j.mayocp.2018.08.001_bib60","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.mayocp.2018.08.001_bib61","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood-2017-02-765891","article-title":"Treating sickle cell disease by targeting HbS polymerization","volume":"129","author":"Eaton","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.mayocp.2018.08.001_bib62","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.121.121","article-title":"SCD-101: a new anti-sickling drug reduces pain and fatigue and improves red blood cell shape in peripheral blood of patients with sickle cell disease","volume":"128","author":"Swift","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib63","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1078\/0944-7113-00040","article-title":"Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with Sickle Cell Disorder","volume":"8","author":"Wambebe","year":"2001","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2141.2002.03593.x","article-title":"In\u00a0vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent","volume":"118","author":"Iyamu","year":"2002","journal-title":"Br J Haematol"},{"issue":"10019","key":"10.1016\/j.mayocp.2018.08.001_bib65","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia\u2014TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2018.08.001_bib66","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/asheducation-2013.1.439","article-title":"Transfusion therapy for sickle cell disease: a balancing act","volume":"2013","author":"Chou","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib67","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3324\/haematol.2010.038307","article-title":"Delayed hemolytic transfusion reaction in children with sickle cell disease","volume":"96","author":"de Montalembert","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bjh.13791","article-title":"Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial","volume":"172","author":"Wood","year":"2016","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.mayocp.2018.08.001_bib69","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.20685","article-title":"Circumstances of death in adult sickle cell disease patients","volume":"81","author":"Darbari","year":"2006","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib70","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1423-0410.2010.01426.x","article-title":"Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century","volume":"100","author":"Dwyre","year":"2011","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib71","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1537-2995.2009.002402.x","article-title":"The risk of transfusion-transmitted infections in sub-Saharan Africa","volume":"50","author":"Jayaraman","year":"2010","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.mayocp.2018.08.001_bib72","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1001\/archinte.1988.00380110115024","article-title":"Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease","volume":"148","author":"Cox","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mayocp.2018.08.001_bib73","first-page":"229","article-title":"Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations","volume":"6","author":"Bhatia","year":"2015","journal-title":"J\u00a0Blood Med"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib74","first-page":"27","article-title":"Availability of related donors for bone marrow transplantation in sickle cell anemia","volume":"16","author":"Mentzer","year":"1994","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.001_bib75","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbmt.2013.02.010","article-title":"Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease","volume":"19","author":"Dallas","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib76","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1701291","article-title":"Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium","volume":"22","author":"Vermylen","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.mayocp.2018.08.001_bib78","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib79","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/bmt.2015.11","article-title":"Traffic Light: prognosis-based eligibility for clinical trials of hematopoietic SCT in adults with sickle cell anemia","volume":"50","author":"Rotz","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib80","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00005792-198801000-00005","article-title":"Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure","volume":"67","author":"Powars","year":"1988","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.001_bib81","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.mayocp.2018.08.001_bib82","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A\u00a0trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.mayocp.2018.08.001_bib83","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bola\u00f1os-Meade","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2018.08.001_bib84","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1083-8791(03)00192-7","article-title":"Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia","volume":"9","author":"Iannone","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.mayocp.2018.08.001_bib85","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","article-title":"Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)","volume":"18","author":"Kamani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.mayocp.2018.08.001_bib86","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/blood.V126.23.543.543","article-title":"Results of a multicenter pilot investigation of bone marrow transplantation in adults with sickle cell disease (STRIDE)","volume":"126","author":"Krishnamurti","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.mayocp.2018.08.001_bib87","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V126.23.619.619","article-title":"A\u00a0multicenter phase II trial of unrelated donor reduced intensity bone marrow transplantation for children with severe sickle cell disease (SCURT): results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study","volume":"126","author":"Shenoy","year":"2015","journal-title":"Blood"},{"issue":"3, suppl","key":"10.1016\/j.mayocp.2018.08.001_bib88","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.bbmt.2015.11.407","article-title":"Results of the Blood and Marrow Transplant Clinical Trials Network Study BMT CTN 0601: SCURT - a multicenter phase II trial of unrelated donor reduced intensity bone marrow transplantation (BMT) for children with severe sickle cell disease","volume":"22","author":"Shenoy","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib89","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.blre.2014.08.001","article-title":"Blood and marrow transplantation for sickle cell disease: is less more?","volume":"28","author":"Bola\u00f1os-Meade","year":"2014","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib90","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.mayocp.2018.08.001_bib91","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/pbc.25608","article-title":"Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment","volume":"62","author":"L\u00ea","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.mayocp.2018.08.001_bib92","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/M18-0185","article-title":"Iatrogenic infertility after curative stem cell transplantation in patients with sickle cell disease","volume":"168","author":"Mishkin","year":"2018","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.mayocp.2018.08.001_bib93","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7577","key":"10.1016\/j.mayocp.2018.08.001_bib94","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.mayocp.2018.08.001_bib95","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jgm.2928","article-title":"Genetic disruption of the KLF1 gene to overexpress the \u03b3-globin gene using the CRISPR\/Cas9 system","volume":"18","author":"Shariati","year":"2016","journal-title":"J\u00a0Gene Med"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib96","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1073\/pnas.92.7.3014","article-title":"Retroviral transfer of a human \u03b2-globin\/\u03b4-globin hybrid gene linked to \u03b2 locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease","volume":"92","author":"Takekoshi","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5550","key":"10.1016\/j.mayocp.2018.08.001_bib97","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1126\/science.1065806","article-title":"Correction of sickle cell disease in transgenic mouse models by gene therapy","volume":"294","author":"Pawliuk","year":"2001","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib98","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","article-title":"Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease","volume":"127","author":"Hoban","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.mayocp.2018.08.001_bib99","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V128.22.1175.1175","article-title":"LentiGlobin gene therapy for transfusion-dependent \u03b2-thalassemia: update from the Northstar Hgb-204 phase 1\/2 clinical study","volume":"128","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.mayocp.2018.08.001_bib100","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1182\/blood.V128.22.1176.1176","article-title":"Interim results from a phase 1\/2 clinical study of LentiGlobin gene therapy for severe sickle cell disease [abstract]","volume":"128","author":"Kanter","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib101","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood-2007-04-081703","article-title":"Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease","volume":"111","author":"Morris","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib102","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1152\/ajpendo.00287.2005","article-title":"In\u00a0vivo rates of erythrocyte glutathione synthesis in adults with sickle cell disease","volume":"291","author":"Reid","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib103","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.thj.6200033","article-title":"A\u00a0comparison in normal individuals and sickle cell patients of reduced glutathione precursors and their transport between plasma and red cells","volume":"1","author":"Kiessling","year":"2000","journal-title":"Hematol J"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib104","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V","article-title":"Oral L-glutamine therapy for sickle cell anemia, I: Subjective clinical improvement and favorable change in red cell NAD redox potential","volume":"58","author":"Niihara","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.mayocp.2018.08.001_bib105","first-page":"4","article-title":"L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells","volume":"5","author":"Niihara","year":"2005","journal-title":"BMC Blood Disord"},{"issue":"21","key":"10.1016\/j.mayocp.2018.08.001_bib106","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood.V124.21.86.86","article-title":"A\u00a0phase 3 study of L-glutamine therapy for sickle cell anemia and sickle \u03b20-thalassemia [abstract]","volume":"124","author":"Niihara","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.mayocp.2018.08.001_bib107","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.V128.22.1318.1318","article-title":"Phase 3 study of L-glutamine therapy in sickle cell anemia and sickle \u03b20-thalassemia subgroup analyses show consistent clinical improvement","volume":"128","author":"Niihara","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2018.08.001_bib108","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1182\/blood.V91.11.4373","article-title":"The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in\u00a0vitro","volume":"91","author":"Gibson","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib109","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10321","article-title":"Effects of N-acetylcysteine on dense cell formation in sickle cell disease","volume":"73","author":"Pace","year":"2003","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.mayocp.2018.08.001_bib110","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1182\/blood.V110.11.3799.3799","article-title":"Anti-oxidant treatment with \u03b1-lipoic acid and acetyl L-carnitine in hemoglobinopathies [abstract]","volume":"110","author":"Lal","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2018.08.001_bib111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12878-017-0075-y","article-title":"Gum Arabic as novel anti-oxidant agent in sickle cell anemia, phase II trial","volume":"17","author":"Kaddam","year":"2017","journal-title":"BMC Hematol"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib112","doi-asserted-by":"crossref","first-page":"e0134156","DOI":"10.1371\/journal.pone.0134156","article-title":"Curcumin attenuates iron accumulation and oxidative stress in the liver and spleen of chronic iron-overloaded rats","volume":"10","author":"Badria","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.001_bib113","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3324\/haematol.2015.124586","article-title":"Dietary \u03c9-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease","volume":"100","author":"Kalish","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib114","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood.V98.6.1955","article-title":"P-selectin mediates the adhesion of sickle erythrocytes to the endothelium","volume":"98","author":"Matsui","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2018.08.001_bib115","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2004-02-0713","article-title":"The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in\u00a0vivo","volume":"104","author":"Embury","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib116","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2010-05-285718","article-title":"Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease","volume":"117","author":"Gutsaeva","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.001_bib117","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2018.08.001_bib118","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2009-12-260513","article-title":"GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice","volume":"116","author":"Chang","year":"2010","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.mayocp.2018.08.001_bib119","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use","volume":"125","author":"Telen","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib120","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2007-04-084061","article-title":"Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion","volume":"111","author":"Chang","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib121","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1182\/blood-2003-07-2209","article-title":"Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes","volume":"103","author":"Turhan","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2018.08.001_bib122","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood.V82.11.3253.3253","article-title":"Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation","volume":"82","author":"Nelson","year":"1993","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib123","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib124","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/cts.12005","article-title":"Effect of propranolol as antiadhesive therapy in sickle cell disease","volume":"5","author":"De Castro","year":"2012","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.mayocp.2018.08.001_bib125","unstructured":"De Castro LM. Propranolol: anti-adhesive SCD treatment; a phase II study of propranolol as anti-adhesive therapy for sickle cell disease. Paper presented at : 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting; April 10, 2015: Hollywood, FL."},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib126","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1365-2141.1998.00627.x","article-title":"Platelet activation in patients with sickle cell disease","volume":"100","author":"Wun","year":"1998","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib127","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc1603499","article-title":"Prasugrel for sickle cell vaso-occlusive events [letter]","volume":"375","author":"Badawy","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib128","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2141.2007.06787.x","article-title":"Phase I study of eptifibatide in patients with sickle cell anaemia","volume":"139","author":"Lee","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.001_bib129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.thromres.2013.08.002","article-title":"A\u00a0pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease","volume":"132","author":"Desai","year":"2013","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib130","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1002\/ajh.25032","article-title":"Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease","volume":"93","author":"Brittain","year":"2018","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.mayocp.2018.08.001_bib131","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2015-05-647107","article-title":"A\u00a0multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children","volume":"126","author":"Brousseau","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2018.08.001_bib132","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jama.2011.235","article-title":"Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial","volume":"305","author":"Gladwin","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.001_bib133","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2010-09-306167","article-title":"Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity","volume":"118","author":"Machado","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2018.08.001_bib134","first-page":"1739","article-title":"NIH and national foundation expenditures for sickle cell disease and cystic fibrosis are associated with PubMed publications and FDA approvals [abstract]","volume":"122","author":"Strouse","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib135","first-page":"CD006786","article-title":"Interventions for treating painful sickle cell crisis during pregnancy","author":"Marti-Carvajal","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib136","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbmt.2017.08.034","article-title":"Ethical challenges in hematopoietic cell transplantation for sickle cell disease","volume":"24","author":"Nickel","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.001_bib137","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood-2014-05-575209","article-title":"The ethics of a proposed study of hematopoietic stem cell transplant for children with \"less severe\" sickle cell disease","volume":"124","author":"Nickel","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib138","first-page":"8","article-title":"Updated mechanisms of sickle cell disease-associated chronic pain","volume":"2","author":"Lutz","year":"2015","journal-title":"Transl Perioper Pain Med"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.001_bib139","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12340","article-title":"Thinking beyond sickling to better understand pain in sickle cell disease","volume":"93","author":"Darbari","year":"2014","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.001_bib140","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/asheducation-2017.1.546","article-title":"Targeting novel mechanisms of pain in sickle cell disease","volume":"2017","author":"Tran","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619618305858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619618305858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:29:56Z","timestamp":1758418196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619618305858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":140,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0025619618305858"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.001","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the Treatment of Sickle Cell Disease","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}